Should patients with a history of ischaemic stroke or transient ischaemic attack be treated with antithrombotic drugs? The answer to this question has been considered to be clear and straightforward for more than two decades.
1,2 However, the question regarding the balance of future intracranial bleeding risk compared with risk of recurrent ischaemic stroke in patients with high burden of cerebral microbleeds remains one of the most complicated problems of modern stroke medicine. 3 In The Lancet Neurology, Duncan Wilson and colleagues 4 aim to elucidate the association between cerebral microbleed burden in baseline neuroimaging and the risk of recurrent stroke. The study was a pooled analysis of individual patient data from 20 322 patients (mean age 70 years [SD 13]) with history of ischaemic stroke or transient ischaemic attack from 38 cohort studies. 4 After a cumulative follow-up of 35 225 patient-years (median 1·34 years [IQR 0·19-2·44]) the investigators documented that cerebral microbleed presence in baseline neuroimaging was associated with increased risk for both ischaemic stroke and intracranial haemorrhage. Despite the fact that the adjusted hazard ratio (aHR) for intracranial haemorrhage was nearly five times higher than that for ischaemic stroke for patients with five or more or ten or more cerebral microbleeds and nearly eight times higher for patients with 20 or more cerebral microbleeds, the absolute rate of ischaemic stroke exceeded that of intracranial haemorrhage even in patients with high (≥20) cerebral microbleed burden. 4 Notably, all associations were independent from cerebral microbleed anatomical dis tribution (lobar vs mixed vs deep), antithrombotic treat ment (antiplatelet or anti coagulant), ethnicity (white vs non-white), age (>80 years vs ≤80 years), and the presence of whitematter hyperintensities on baseline neuroimaging or the diagnosis of probable cerebral amyloid angiopathy. 4 The main strengths of this study are the large sample size, including almost all available findings from published and unpublished cohort studies of adults with recent ischaemic stroke or transient ischaemic attack using appropriate MRI sequence sensitive to magnetic susceptibility, the prospective study design with strict inclusion and exclusion criteria, and the comprehensive, prespecified, and robust statistical analysis plan. This study offers novel and clinically relevant information that in patients with recent ischaemic stroke or transient ischaemic attack the absolute risk of ischaemic stroke is higher than that of intracranial haemorrhage, regardless of cerebral microbleed presence, burden, or pattern and independently of their secondary prevention treat ment with antiplatelets or oral anticoagulants. Notably, the individual-patient-data meta-analysis credibly contradicts the findings of a previous meta-analysis that did not detect any association between cerebral microbleed presence or burden and recurrent ischaemic stroke in patients with ischaemic stroke treated with oral anticoagulants. 5 However, the observational study design is prone to residual confounding, and selection and indication biases. Furthermore, the investigators were unable to adjust for other cofounders in their multivariable models, including MRI field strength, other secondary prevention therapies (eg, statins), and vascular risk factors such as diabetes mellitus and chronic kidney disease.
Additionally, no central adjudication of the outcome events and no formal assessment of recurrent stroke severity and residual disability were done. The authors report the absence of any interaction between oral anticoagulant type (vitamin K antagonists [vs nonvitamin K oral anticoagulants]) and cerebral microbleed presence for the outcomes of recurrent ischaemic stroke and intracranial haemorrhage, but this finding might be attributed to the modest number of outcome events and particularly intracranial haemorrhages (n=91) as well as to potential imbalances between vitamin K antagonists (n=5253) and non-vitamin K oral anticoagulants (n=2484) subgroups. The protective effect of non-vitamin K oral anticoagulants (compared with vitamin K antagonists) in the risk of incident intracranial bleeding in patients with atrial fibrillation receiving anticoagulation for secondary stroke prevention has been well established. 6 In conclusion, the study by Wilson and colleagues 4 highlights that the absolute risk of recurrent ischaemic stroke consistently exceeds the absolute risk of intracranial haemorrhage in patients with a history of ischaemic stroke or transient ischaemic attack even in the presence of high cerebral microbleed load (≥20). These find ings suggest that cerebral microbleed presence, burden, and pattern on neuroimaging should
